Ontogenetic role of angiontensin-converting enzyme in rats: thirst and sodium appetite evaluation.
We investigated the influence of captopril (an angiotensin converting enzyme inhibitor) treatment during pregnancy and lactation period on hydromineral balance of the male adult offspring, particularly, concerning thirst and sodium appetite. We did not observe significant alterations in basal hydromineral (water intake, 0.3M NaCl intake, volume and sodium urinary concentration) or cardiovascular parameters in adult male rats perinatally treated with captopril compared to controls. However, male offspring rats that perinatally exposed to captopril showed a significant attenuation in water intake induced by osmotic stimulation, extracellular dehydration and beta-adrenergic stimulation. Moreover, captopril treatment during perinatal period decreased the salt appetite induced by sodium depletion. This treatment also attenuated thirst and sodium appetite aroused during inhibition of peripheral angiotensin II generation raised by low concentration of captopril in the adult offspring. Interestingly, perinatal exposure to captopril did not alter water or salt intake induced by i.c.v. administration of angiotensin I or angiotensin II. These results showed that chronic inhibition of angiotensin converting enzyme during pregnancy and lactation modifies the regulation of induced thirst and sodium appetite in adulthood.
Mecawi
André S
AS
Department of Physiological Sciences, Institute de Biology, Federal Rural University of Rio de Janeiro, 23890-000, Seropédica, RJ, Brazil.
Araujo
Iracema G
IG
Rocha
Fábio F
FF
Coimbra
Terezila M
TM
Antunes-Rodrigues
José
J
Reis
Luís C
LC
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000704:Analysis of Variance; D000803:Angiotensin I / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001066:Appetite / Q000187:drug effects / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology; D003681:Dehydration / Q000473:pathology / Q000503:physiopathology; D004234:Diuretics, Osmotic / Q000494:pharmacology; D004326:Drinking / Q000187:drug effects / Q000502:physiology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007276:Injections, Intraventricular / Q000379:methods; D007545:Isoproterenol / Q000494:pharmacology; D007668:Kidney / Q000166:cytology / Q000187:drug effects; D007774:Lactation / Q000187:drug effects; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D012965:Sodium Chloride / Q000652:urine; D012982:Sodium, Dietary / Q000494:pharmacology; D013894:Thirst / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004234:Diuretics, Osmotic; D012982:Sodium, Dietary; D000804:Angiotensin II; D012965:Sodium Chloride; D000803:Angiotensin I; D002216:Captopril; D007703:Peptidyl-Dipeptidase A; D007545:Isoproterenol